Published in Neurology on August 21, 2007
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med (2011) 2.69
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol (2009) 2.06
Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med (2010) 1.70
Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann Neurol (2011) 1.67
An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol (2010) 1.57
Organ-specific features of natural killer cells. Nat Rev Immunol (2011) 1.48
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol (2009) 1.42
Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol (2010) 1.35
Daclizumab therapy for multiple sclerosis. Neurotherapeutics (2013) 1.33
Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis. Arthritis Rheum (2009) 1.23
Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol (2013) 1.16
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol (2013) 1.13
The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol (2014) 1.11
Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology (2011) 1.08
Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations. J Neurol (2008) 1.08
Permeation of blood-borne IL15 across the blood-brain barrier and the effect of LPS. J Neurochem (2008) 1.06
Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol (2007) 1.05
Cessation of blood-to-brain influx of interleukin-15 during development of EAE. J Cereb Blood Flow Metab (2009) 1.00
A novel monoclonal antibody specific for canine CD25 (P4A10): selection and evaluation of canine Tregs. Vet Immunol Immunopathol (2009) 0.99
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. Ann Clin Transl Neurol (2015) 0.96
Subsets of human natural killer cells and their regulatory effects. Immunology (2014) 0.93
Monoclonal antibodies in treatment of multiple sclerosis. Clin Exp Immunol (2014) 0.91
Multiple sclerosis treatment and infectious issues: update 2013. Clin Exp Immunol (2014) 0.90
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2014) 0.89
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord (2013) 0.87
Natural killer cells and their receptors in multiple sclerosis. Brain (2012) 0.87
Thrombotic microangiopathy in haematopoietic cell transplantation: an update. Mediterr J Hematol Infect Dis (2010) 0.85
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (2009) 0.85
Escalating immunotherapy of multiple sclerosis. Ther Adv Neurol Disord (2008) 0.84
Polymorphisms in the IL2, IL2RA and IL2RB genes in multiple sclerosis risk. Eur J Hum Genet (2010) 0.83
CNS vasculitis in a patient with MS on daclizumab monotherapy. Neurology (2013) 0.81
Emerging immunopharmacological targets in multiple sclerosis. J Neurol Sci (2015) 0.81
Innovative monoclonal antibody therapies in multiple sclerosis. Ther Adv Neurol Disord (2008) 0.80
Recent developments in multiple sclerosis therapeutics. BMC Med (2009) 0.79
Monoclonal antibodies in multiple sclerosis treatment: current and future steps. Ther Adv Neurol Disord (2009) 0.79
Recent clinical trials and future therapies. J Neurol (2008) 0.79
Promising treatments of tomorrow for multiple sclerosis. Ann Indian Acad Neurol (2009) 0.79
Monoclonal antibodies in the therapy of multiple sclerosis: an overview. J Neurol (2008) 0.79
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord (2015) 0.76
Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (2016) 0.75
Daclizumab. Hosp Pharm (2016) 0.75
Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis. Drug Des Devel Ther (2013) 0.75
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis. Biologics (2016) 0.75
Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system. Clin Exp Immunol (2014) 0.75
Targeted immunotherapy trials for idiopathic inflammatory myopathies. J Neurol (2012) 0.75
On the thymus in the differentiation of "H-2 self-recognition" by T cells: evidence for dual recognition? J Exp Med (1978) 9.51
Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest (2001) 5.94
The major histocompatibility complex of the mouse. Science (1979) 4.76
Serologically defined and lymphocyte-defined components of the major histocompatibility complex in the mouse. J Exp Med (1972) 4.59
Divergence time and population size in the lineage leading to modern humans. Theor Popul Biol (1995) 4.31
The lymphoreticular system in triggering virus plus self-specific cytotoxic T cells: evidence for T help. J Exp Med (1978) 4.27
Genetic control of the immune response. Mapping of the Ir-1 locus. J Exp Med (1972) 3.96
The H-2 model for the major histocompatibility systems. Transplant Rev (1971) 3.82
List of congenic lines of mice. I. Lines with differences at alloantigen loci. Transplantation (1973) 3.73
Bracteomania, an inflorescence anomaly, is caused by the loss of function of the MADS-box gene squamosa in Antirrhinum majus. EMBO J (1992) 3.60
Cell-mediated lympholysis. Importance of serologically defined H-2 regions. J Exp Med (1973) 3.34
Serological identification of an Ir-region product. Science (1973) 3.32
The traditional and a new version of the mouse H-2 complex. Nature (1981) 3.12
Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet (2001) 2.79
MHC polymorphism pre-dating speciation. Nature (1988) 2.70
Therapy for acute otitis media. Preference of parents for oral or parenteral antibiotic. Arch Pediatr Adolesc Med (1996) 2.68
H-2 haplotypes, genes and antigens: second listing. II. The H-2 complex. Immunogenetics (1983) 2.62
Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr (1988) 2.62
Origin of major histocompatibility complex polymorphism: the trans-species hypothesis. Hum Immunol (1987) 2.51
Cytotoxic T cells learn specificity for self H-2 during differentiation in the thymus. Nature (1978) 2.51
The polymer mat: arrested rebound of a compressed polymer layer. Eur Phys J E Soft Matter (2002) 2.43
Phylogeny of Darwin's finches as revealed by mtDNA sequences. Proc Natl Acad Sci U S A (1999) 2.42
Genetic and immunological complexity of major histocompatibility regions. Science (1972) 2.40
Polymorphism and balancing selection at major histocompatibility complex loci. Genetics (1992) 2.34
Directly measured second hand smoke exposure and asthma health outcomes. Thorax (2005) 2.32
Molecular characterisation of the Arabidopsis SBP-box genes. Gene (1999) 2.31
Ir-genes in H-2 regulate generation of anti-viral cytotoxic T cells. Mapping to K or D and dominance of unresponsiveness. J Exp Med (1978) 2.24
Socio-economic disparities in preterm birth: causal pathways and mechanisms. Paediatr Perinat Epidemiol (2001) 2.19
Hair concentrations of nicotine and cotinine in women and their newborn infants. JAMA (1994) 2.18
Evolution of the major histocompatibility complex. Crit Rev Immunol (1986) 2.16
Essential role of insulin receptor substrate 1 in differentiation of brown adipocytes. Mol Cell Biol (2001) 2.14
Degradation of phenanthrene, fluorene and fluoranthene by pure bacterial cultures. Appl Microbiol Biotechnol (1990) 2.12
H-2 mutations: their genetics and effect on immune functions. Adv Immunol (1978) 2.11
Nucleotide sequences of chimpanzee MHC class I alleles: evidence for trans-species mode of evolution. EMBO J (1988) 1.98
Serologic evidence for antigens controlled by the Ir region in mice. J Exp Med (1973) 1.94
Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med (1990) 1.91
Graft-versus-host reactions across different regions of the H-2 complex of the mouse. J Exp Med (1973) 1.87
Isolation of Borrelia burgdorferi from the myocardium of a patient with longstanding cardiomyopathy. N Engl J Med (1990) 1.83
Fluidity of water confined to subnanometre films. Nature (2001) 1.80
Tissue distribution of I region-associated antigens in the mouse. J Immunol (1974) 1.76
Production of anti-H-2 antibodies in thymectomized mice. Eur J Immunol (1974) 1.74
DNA archives and our nearest relative: the trichotomy problem revisited. Mol Phylogenet Evol (2000) 1.71
H-2 types of translocation stocks T(2;9)138Ca, T(9;13)-190Ca and an H-2 recombinant. Transplantation (1970) 1.71
Evidence supporting a two-gene model for the H-2 histocompatibility system of the mouse. J Exp Med (1972) 1.70
Essential role of insulin receptor substrate-2 in insulin stimulation of Glut4 translocation and glucose uptake in brown adipocytes. J Biol Chem (2000) 1.67
Genetics of the major histocompatibility complex: the final act. Annu Rev Immunol (1983) 1.65
Anaesthesia in haemodynamically compromised emergency patients: does ketamine represent the best choice of induction agent? Anaesthesia (2009) 1.64
Polymorphism of the mouse H-2 loci. Immunol Rev (1981) 1.63
Determination of gestational cocaine exposure by hair analysis. JAMA (1989) 1.63
Natural history of left ventricular thrombi: their appearance and resolution in the posthospitalization period of acute myocardial infarction. J Am Coll Cardiol (1990) 1.61
Graft versus host reaction in strains of mice identical for H-2K and H-2D antigens. Nat New Biol (1973) 1.61
Intensity of natural selection at the major histocompatibility complex loci. Proc Natl Acad Sci U S A (1994) 1.59
The origin and age of haplochromine fishes in Lake Victoria, east Africa. Proc Biol Sci (2000) 1.59
Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child (1989) 1.59
In irradiation chimeras, K or D regions of the chimeric host, not of the donor lymphocytes, determine immune responsiveness of antiviral cytotoxic T cells. J Exp Med (1978) 1.57
Private and public antigens of the mouse H-2 system. Nature (1971) 1.53
Cytological identification of the chromosome carrying the IXth linkage group (including H-2) in the house mouse. Proc Natl Acad Sci U S A (1971) 1.51
Structure of the murine Ia-associated invariant (Ii) chain as deduced from a cDNA clone. EMBO J (1984) 1.51
Characterization of Ia antigens in mouse serum. J Immunol (1976) 1.51
Responder T cells depleted of alloreactive cells react to antigen presented on allogeneic macrophages from nonresponder strains. J Exp Med (1981) 1.49
Hostility and myocardial ischemia in coronary artery disease patients: evaluation by gender and ischemic index. Psychosom Med (1993) 1.48
Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant (2000) 1.48
Borrelia burgdorferi as an etiologic agent in chronic heart failure? Scand J Infect Dis Suppl (1991) 1.48
On the origin of Darwin's finches. Mol Biol Evol (2001) 1.46
Primary in vitro cell-mediated lympholysis reaction of NZB mice against unmodified targets syngeneic at the major histocompatibility complex. J Exp Med (1978) 1.45
Genetic organization and evolution of the mouse H-2 region: a duplication model. Transplant Proc (1971) 1.44
Ontogeny of Ia and IgD on IgM-bearing B lymphocytes in mice. J Exp Med (1977) 1.44
Congenic mouse strains with different immunoglobulin allotypes. I. Breeding scheme, histocompatibility tests, and kinetics of gamma G2a-globulin production by transferred cells for C3H.SW and its congenic partner CWB/5. Transplantation (1967) 1.44
Identification and characterization of amelogenin genes in monotremes, reptiles, and amphibians. Proc Natl Acad Sci U S A (1998) 1.43
The H-2 system: past and present. Transplant Proc (1973) 1.42
Ia antigens as restriction molecules in Ir-gene controlled T-cell proliferation. Immunol Rev (1981) 1.42
Helical body CT: evolution of scanning protocols. AJR Am J Roentgenol (1998) 1.42
Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett (2001) 1.42
Candida infective endocarditis. Eur J Clin Microbiol Infect Dis (2008) 1.41
Isolation of 37 single-copy DNA probes from human chromosome 6 and physical mapping of 11 probes by in situ hybridization. Genomics (1991) 1.40
Reprinted article "A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery". Eur J Vasc Endovasc Surg (2011) 1.40
A randomized, double-blind comparison of lumbar epidural and intravenous fentanyl infusions for postthoracotomy pain relief. Analgesic, pharmacokinetic, and respiratory effects. Anesthesiology (1992) 1.39
Does the Child Behavior Checklist predict levels of preoperative anxiety at anesthetic induction and postoperative emergence delirium? A prospective cohort study. Minerva Anestesiol (2014) 1.39
The changing face of the laboratory. Br Med J (Clin Res Ed) (1981) 1.38
Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit (1993) 1.36
Persistence of neutral polymorphisms in Lake Victoria cichlid fish. Proc Natl Acad Sci U S A (1998) 1.36
The synonymous substitution rate of the major histocompatibility complex loci in primates. Proc Natl Acad Sci U S A (1993) 1.34
Induction of regulatory T-lymphocyte responses by liposomes carrying major histocompatibility complex molecules and foreign antigen. Nature (1985) 1.34
The control of differentiation by the T complex. Immunol Rev (1977) 1.34
Inbred and wild mice carry identical deletions in their E alpha MHC genes. EMBO J (1985) 1.33
The two standards of care for tumescent liposuction. Dermatol Surg (1997) 1.33
Molecular genetics of speciation and human origins. Proc Natl Acad Sci U S A (1994) 1.31
A novel linear amphipathic beta-sheet cationic antimicrobial peptide with enhanced selectivity for bacterial lipids. J Biol Chem (2001) 1.30
Ia antigens: their serology, molecular relationships, and their role in allograft reactions. Transplant Rev (1976) 1.28
Neonatally tolerant mice fail to react against virus-infected tolerated cells. Nature (1977) 1.27
Genetic control of T-cell proliferative responses to poly(glu40ala60) and poly(glu51lys34tyr15): subregion-specific inhibition of the responses with monoclonal Ia antibodies. Immunogenetics (1980) 1.27
Issues regarding health plan payments under Medicare and recommendations for reform. Milbank Q (1992) 1.26
B cell differentiation induced by lipopolysaccharide. V. Suppression of plasma cell maturation by anti-mu: mode of action and characteristics of suppressed cells. J Immunol (1978) 1.26
Potassium regulates IL-1 beta processing via calcium-independent phospholipase A2. J Immunol (2000) 1.25
Mapping of mhc class I and class II regions to different linkage groups in the zebrafish, Danio rerio. Immunogenetics (1997) 1.25
Evolutionary relationships between the t and H-2 haplotypes in the house mouse. Immunogenetics (1984) 1.24
Relationship between trinitrophenyl and H-2 antigens on trinitrophenyl-modified spleen cells. I. H-2 antigens on cells treated with trinitrobenzene sulfonic acid are derivatized. J Immunol (1977) 1.23
Extensive MHC variability in cichlid fishes of Lake Malawi. Nature (1993) 1.23
Pharmacological inhibition of the lateral habenula improves depressive-like behavior in an animal model of treatment resistant depression. Behav Brain Res (2010) 1.23
H-2-controlled suppression of T cell response to lactate dehydrogenase B. Characterization of the lactate dehydrogenase B suppressor pathway. J Exp Med (1982) 1.22